Pharmacologic Approaches to Glycemic Control in Adults with Type-2 Diabetes

Sanjay Srivasta*

Endocrinology Department, American Institute of Diabetes & Endocrinology, India

Corresponding Author*

Sanjay Srivasta

Endocrinology Department, American Institute of Diabetes & Endocrinology, India

E-mail: ss.sanjay@gmail.com

Received: 01-Oct-2024, Manuscript No. jdm-24-35323; **Editor assigned:** 03-Oct-2024, PreQC No. jdm-24-35323; **Reviewed:** 17-Oct-2024, QC No. jdm-24-35323; **Revised:** 22-Oct-2024, Manuscript No. jdm-24-35323; **Published:** 29-Oct-2024, DOI: 10.35248/2155-6156.10001172

Abstract

Type 2 Diabetes (T2D) is a chronic metabolic disorder characterized by hyperglycemia resulting from insulin resistance and impaired insulin secretion. Effective pharmacologic management is essential for preventing complications such as cardiovascular disease, nephropathy, neuropathy, and retinopathy. This article provides an overview of the pharmacological agents used in the management of T2D, including the role of insulin, oral agents, and newer classes of drugs like GLP-1 receptor agonists and SGLT2 inhibitors. The mechanisms, efficacy, safety profiles, and clinical applications of these therapies are discussed. Additionally, the importance of individualized treatment plans, patient education, and monitoring are emphasized to achieve optimal glycemic control.

Keywords: Type 2 diabetes; Glycemic control; Insulin resistance; Pharmacological therapy; GLP-1 agonists; SGLT2 inhibitors; Metformin; Insulin; Cardiovascular risk

Introduction

Type 2 diabetes (T2D) is a major global health concern, with rising prevalence rates due to lifestyle factors such as poor diet and lack of physical activity. It is characterized by a combination of insulin resistance and beta-cell dysfunction, leading to chronic hyperglycemia. If left untreated, T2D can result in serious complications, including cardiovascular disease, kidney failure, neuropathy, and blindness. Pharmacological interventions play a central role in managing glycemic levels, improving insulin sensitivity, and preventing long-term complications. The pharmacologic management of T2D has evolved over the past few decades, with new classes of drugs providing more effective and personalized treatment options. This article reviews the current pharmacologic therapies for T2D, focusing on their mechanisms of action, efficacy, safety, and role in managing the disease [1-3].

Description

1. Metformin

Metformin, a biguanide, is the first-line treatment for T2D. It primarily works by reducing hepatic glucose production and improving insulin sensitivity. It does not cause weight gain and has a relatively low risk of hypoglycemia, making it a preferred option for many patients. Additionally, metformin has demonstrated cardiovascular benefits, and recent studies suggest that it may help in reducing the risk of cancer.

2. Sulfonylureas

Sulfonylureas, such as glibenclamide and glimepiride, stimulate insulin release from the pancreatic beta-cells. While effective in lowering blood glucose, sulfonylureas are associated with a higher risk of hypoglycemia and weight gain. These agents are often used in combination with other drugs when metformin alone is insufficient [4,5].

3. Thiazolidinediones (TZDs)

TZDs, including pioglitazone, improve insulin sensitivity by acting on the peroxisome proliferator-activated receptor-gamma (PPAR-γ). These drugs help reduce insulin resistance in peripheral tissues like muscle and adipose tissue. However, they are associated with side effects such as weight gain, fluid retention, and an increased risk of heart failure in some patients.

4. DPP-4 inhibitors

Dipeptidyl peptidase-4 (DPP-4) inhibitors, such as sitagliptin and saxagliptin, work by preventing the breakdown of incretin hormones, thereby increasing insulin secretion in response to meals and decreasing glucagon levels. These agents are weight-neutral and have a low risk of hypoglycemia, making them a useful option for many patients. However, their effects on cardiovascular outcomes remain uncertain [6,7].

5. GLP-1 receptor agonists

Glucagon-like peptide-1 (GLP-1) receptor agonists, such as liraglutide and semaglutide, mimic the action of the natural incretin hormone GLP-1. They enhance insulin secretion, inhibit glucagon release, slow gastric emptying, and promote satiety. These agents have shown significant benefits in terms of weight loss and cardiovascular risk reduction, making them a promising therapy for patients with T2D and cardiovascular disease.

6. SGLT2 inhibitors

Sodium-glucose cotransporter 2 (SGLT2) inhibitors, including empagliflozin and canagliflozin, work by inhibiting glucose reabsorption in the kidneys, leading to increased urinary glucose excretion. These agents not only improve glycemic control but also provide cardiovascular and renal benefits. They are particularly beneficial in patients with T2D and comorbid conditions such as heart failure or chronic kidney disease [8].

7. Insulin therapy

Although insulin resistance is a hallmark of T2D, many patients eventually require insulin therapy to maintain optimal glycemic control. Insulin can be used in combination with other agents or as monotherapy in patients who have progressed to a state where oral medications are no longer effective. Various insulin formulations, including long-acting (e.g., glargine) and rapid-acting (e.g., aspart) insulins, allow for tailored therapy depending on the patient's needs.

Discussion

The management of T2D requires an individualized approach, taking into consideration the patient's glycemic control goals, comorbid conditions, risk factors for cardiovascular disease, and preferences. The recent introduction of newer agents such as GLP-1 receptor agonists and SGLT2 inhibitors has significantly improved the treatment landscape by addressing not only glycemic control but also weight management and cardiovascular risk. These therapies have shown evidence of reducing hospitalizations for heart failure, improving renal outcomes, and offering additional benefits beyond glucose lowering. While combination therapy is often necessary to achieve optimal glycemic control, clinicians must carefully select agents based on the patient's clinical profile. For example, metformin remains the cornerstone

of T2D therapy, but in patients with heart failure or chronic kidney disease, SGLT2 inhibitors may be preferred. Similarly, GLP-1 receptor agonists are beneficial in patients who are overweight or obese. The safety profiles of these drugs also vary, and clinicians must be mindful of potential side effects, including gastrointestinal issues with GLP-1 receptor agonists, fluid retention with TZDs, and the risk of hypoglycemia with sulfonylureas and insulin [9,10].

Conclusion

Pharmacologic management of type 2 diabetes (T2D) is rapidly advancing, offering diverse treatment options tailored to individual needs. Effective management involves combining medications with lifestyle interventions, including diet and exercise, to achieve and maintain glycemic targets while minimizing complications. Treatment plans are customized based on factors such as glycemic goals, comorbid conditions, and patient preferences. Emerging therapies, such as GLP-1 receptor agonists and SGLT2 inhibitors, have expanded the therapeutic landscape, providing cardiovascular and renal benefits alongside glucose control. As research progresses, clinical trials continue to refine the strategic use of these agents across varied patient populations, emphasizing personalized care.

References

1. Al Dawish MA, Robert AA (2021) COVID-19 in people with diabetes: epidemiological perspectives and public health actions in the Middle East and north africa (MENA) region. Curr Diabetes Rev 17: 1-6.
2. Sah AK, Vyas A, Suresh PK, Gidwani B (2018) Application of nanocarrier-based drug delivery system in treatment of oral cancer. Artif Cells Nanomed Biotechnol 46: 650-657.
3. Wen Y, Oh JK (2015) Intracellular delivery cellulose-based bionanogels with dual temperature/pH-response for cancer therapy. Colloids Surf B Biointerfaces 133: 246-253.
4. Al Hayek AA, Robert AA, Matar AB, Algarni A, Alkubedan H, et al. (2020) Risk factors for hospital admission among COVID-19 patients with diabetes. Saudi Med J 41: 1090-1097.
5. Robert AA, Al Dawish MA (2021) COVID-19 in people with diabetes: perspectives from Saudi Arabia. Curr Diabetes Rev 17: 1-6
6. Ahmad A, Atique S, Balkrishnan R, Patel I (2014) Pharmacy profession in India: Currentscenario and Recommendations. Ind J Pharm Edu Res 48: 12-15.
7. de Matos-Neto EM, Lima JD, de Pereira WO, Figueredo RG, Riccardi DM, et al. (2015) Systemic inflammation in cachexia-is tumor cytokine expression profile the culprit?. Front Immunol 6: 629.
8. Iacobellis G (2020) COVID-19 and diabetes: can DPP4 inhibition play a role?. Diabetes Res Clin Pract 162: 108125.
9. Unsoy G, Gunduz U (2018) Smart Drug Delivery Systems in Cancer Therapy. Curr Drug Targets 19: 202-212.
10. Agrawal M, Saraf S, Saraf S, Antimisiaris SG, Chougule MB, et al. (2018) Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. J Control Release 281: 139-177.

Cite this article: Sanjay Srivasta. Pharmacologic Approaches to Glycemic Control in Adults with Type-2 Diabetes. J Diabetes Metab, 2024, 15(10): 1172.